India needs holistic approach if it is to keep up with rivals in pharma nanotech, says BCG
This article was originally published in Scrip
If it is to keep pace with China and Russia, India needs to put in place effective policies and systems, backed by vibrant funding options, to unlock potential in the nanotechnology segment, especially in oncology.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.